Alberto F. Sobrero, MD

Clinical interpretation and validity of clinical trials: When do they become practice changing?

07/09/2018

Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS

Introduction In the Phase III RECOURSE study, patients with metastatic colorectal cancer (mCRC) refractory to standard therapies demonstrated significantly extended overall survival and ...

Eric Van Cutsem , MD, PhD;

Alberto F. Sobrero , MD;

A. Ohtsu ;

Josep Tabernero , MD, PhD;

G. Argiles ;

R. Mayer ;

L. Vidot ;

S. Vera Moreno ;

07/01/2019

Debate: 3 Months of CAPOX Should be The Standard of Care For All Stage 3 Colon Cancer Patients: Yes

Alberto F. Sobrero , MD;

07/03/2021

25 Years of Progress in Colorectal Cancer Treatment

Alberto F. Sobrero , MD;

07/07/2023

Alberto Sobrero, MD, Ospedale San Martino

Videos

Groundbreaking Advancements in Colorectal Cancer From the Past 25 Years

08/23/2023

Alberto F. Sobrero , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Alberto Sobrero, MD, highlighted key advancements in colorectal cancer from the past 25 years.

At the 2023 World Congress on...

08/23/2023

Oncology